Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA opens up new avenues for individualized cance...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yan Peng, Wuxuan Mei, Kaidong Ma, Changchun Zeng
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	circulating tumor DNA minimum residual disease (MRD) biomarker liquid biopsy cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6e3c221d463c466ba5b4c9263ea35e00
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6e3c221d463c466ba5b4c9263ea35e00
record_format	dspace
spelling	oai:doaj.org-article:6e3c221d463c466ba5b4c9263ea35e002021-11-18T08:58:14ZCirculating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives2234-943X10.3389/fonc.2021.763790https://doaj.org/article/6e3c221d463c466ba5b4c9263ea35e002021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.763790/fullhttps://doaj.org/toc/2234-943XCirculating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA opens up new avenues for individualized cancer diagnosis and therapy in various types of tumors. Evidence suggests that minimum residual disease (MRD) is closely associated with disease recurrence, thus identifying specific genetic and molecular alterations as novel MRD detection targets using ctDNA has been a research focus. MRD is considered a promising prognostic marker to identify individuals at increased risk of recurrence and who may benefit from treatment. This review summarizes the current knowledge of ctDNA and MRD in solid tumors, focusing on the potential clinical applications and challenges. We describe the current state of ctDNA detection methods and the milestones of ctDNA development and discuss how ctDNA analysis may be an alternative for tissue biopsy. Additionally, we evaluate the clinical utility of ctDNA analysis in solid tumors, such as recurrence risk assessment, monitoring response, and resistance mechanism analysis. MRD detection aids in assessing treatment response, patient prognosis, and risk of recurrence. Moreover, this review highlights current advancements in utilizing ctDNA to monitor the MRD of solid tumors such as lung cancer, breast cancer, and colon cancer. Overall, the clinical application of ctDNA-based MRD detection can assist clinical decision-making and improve patient outcomes in malignant tumors.Yan PengWuxuan MeiKaidong MaChangchun ZengFrontiers Media S.A.articlecirculating tumor DNAminimum residual disease (MRD)biomarkerliquid biopsycancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	circulating tumor DNA minimum residual disease (MRD) biomarker liquid biopsy cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	circulating tumor DNA minimum residual disease (MRD) biomarker liquid biopsy cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Yan Peng Wuxuan Mei Kaidong Ma Changchun Zeng Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
description	Circulating tumor DNA (ctDNA) is cell-free DNA (cfDNA) fragment in the bloodstream that originates from malignant tumors or circulating tumor cells. Recently, ctDNA has emerged as a promising non-invasive biomarker in clinical oncology. Analysis of ctDNA opens up new avenues for individualized cancer diagnosis and therapy in various types of tumors. Evidence suggests that minimum residual disease (MRD) is closely associated with disease recurrence, thus identifying specific genetic and molecular alterations as novel MRD detection targets using ctDNA has been a research focus. MRD is considered a promising prognostic marker to identify individuals at increased risk of recurrence and who may benefit from treatment. This review summarizes the current knowledge of ctDNA and MRD in solid tumors, focusing on the potential clinical applications and challenges. We describe the current state of ctDNA detection methods and the milestones of ctDNA development and discuss how ctDNA analysis may be an alternative for tissue biopsy. Additionally, we evaluate the clinical utility of ctDNA analysis in solid tumors, such as recurrence risk assessment, monitoring response, and resistance mechanism analysis. MRD detection aids in assessing treatment response, patient prognosis, and risk of recurrence. Moreover, this review highlights current advancements in utilizing ctDNA to monitor the MRD of solid tumors such as lung cancer, breast cancer, and colon cancer. Overall, the clinical application of ctDNA-based MRD detection can assist clinical decision-making and improve patient outcomes in malignant tumors.
format	article
author	Yan Peng Wuxuan Mei Kaidong Ma Changchun Zeng
author_facet	Yan Peng Wuxuan Mei Kaidong Ma Changchun Zeng
author_sort	Yan Peng
title	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
title_short	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
title_full	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
title_fullStr	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
title_full_unstemmed	Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
title_sort	circulating tumor dna and minimal residual disease (mrd) in solid tumors: current horizons and future perspectives
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/6e3c221d463c466ba5b4c9263ea35e00
work_keys_str_mv	AT yanpeng circulatingtumordnaandminimalresidualdiseasemrdinsolidtumorscurrenthorizonsandfutureperspectives AT wuxuanmei circulatingtumordnaandminimalresidualdiseasemrdinsolidtumorscurrenthorizonsandfutureperspectives AT kaidongma circulatingtumordnaandminimalresidualdiseasemrdinsolidtumorscurrenthorizonsandfutureperspectives AT changchunzeng circulatingtumordnaandminimalresidualdiseasemrdinsolidtumorscurrenthorizonsandfutureperspectives
_version_	1718421087930286080

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Ejemplares similares